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Abstract
Tryptase(+) mast cells (MCs), abundant in the invasive front of tumours, contribute to tissue remodelling. Indeed, protease-activated receptor-
2 (PAR-2) activation by MC-tryptase is considered an oncogenic event in colorectal cancer (CRC). Recently, we have suggested NHERF1 as a
potential new marker in CRC. In this study, we aimed to determine the distribution of tryptase(+) MCs and PAR-2 and to examine the relation-
ship between PAR-2 and NHERF1, investigating their reputed usefulness as tumour markers. We studied a cohort of 115 CRC specimens
including primary cancer (C) and adjacent normal mucosa (NM) by immunohistochemical double staining, analyzing the protein expression of
MC-tryptase, PAR-2 and cytoplasmic NHERF1. MC density was higher in NM than in C. Tumours with high TNM stage and poor grade showed
the highest MC density. A higher PAR-2 immunoreactivity characterized tumours most infiltrated by MCs compared with samples with low MC
density. Furthermore, PAR-2 overexpression was associated with advanced TNM stage, poor grade and lymphovascular invasion (LVI). A posi-
tive correlation existed between tryptase(+) MC density and PAR-2 expression. Cytoplasmic NHERF1 was higher in C than in NM and overex-
pressing tumours resulted associated with nodal and distant metastases, poor grade and LVI. PAR-2 correlated with cytoplasmic NHERF1 and
the PAR-2(+)/cytoplasmic NHERF1(+) expression immunophenotype identified tumours associated with unfavourable prognosis and aggressive
clinical parameters. Our data indicate that the high density of tryptase(+) MCs at invasive margins of tumours was associated with advanced
stages of CRC and was strongly correlated with PAR-2 expression.
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Introduction
Cancer-related inflammation is a key component of tumours and has
been suggested as the seventh hallmark of cancer progression [1]. In
fact, patients with inflammatory bowel disease, Crohn’s disease and
chronic ulcerative colitis have a much higher risk of CRC [2, 3]. MCs
play a role as cancer promoters through various molecular and cellu-
lar mechanisms, including participation in immunosuppression,
release of pro-angiogenic and mitogenic factors and remodelling of
the tumour microenvironment [4–6]. MCs contribute to tissue remod-
elling through a rich number of proteases, including tryptase. Indeed,
tryptase(+) MCs have been found to be abundant in the invasive front
of tumours [7].
It is well-established that a subclass of proteases acts as signal
molecules controlling cell functions through PARs, a subfamily of
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specific G protein–coupled receptors consisting of four members
designated PAR1-4 [8]. In particular, PAR-2 is activated by multiple
trypsin-like enzymes including trypsin and MC-tryptase, contribut-
ing to a range of normal and disease processes including cancer.
Activation of PAR-2 is an oncogenic event in colon cancer [9] and
it may facilitate the progression of CRC [10, 11]. MC-tryptase
cleaves and activates PAR-2 on gut epithelial cells and myocytes
[12, 13]. PAR-2 activity also stimulates proliferation of colon can-
cer cells and induces the expression of the prostaglandin-
synthesizing enzyme COX2 and its metabolite prostaglandin-E2
[14]. Moreover, recent studies have shown that the PAR-2/trypsin
system facilitates colorectal carcinogenesis by promoting cell prolif-
eration, migration and invasion [15].
Signalling pathways are assembled into multi-protein signalling
complexes by scaffolding proteins that permit the creation of new
tumour-specific pathways to drive the subverted cellular functions
exhibited by tumour cells [16]. The Na+/H+ exchanger regulating fac-
tor 1 (NHERF1, also named SLC9A3R1) is an adaptor protein that
functions as a regulator of transmembrane receptors, transporters
and other proteins localized at or near the plasma membrane [17]
and is considered a new player in CRC progression [18]. Recently, we
have suggested that nuclear NHERF1 could be a potential new mar-
ker, representing an early indicator of pre-morphological triggering of
CRC carcinogenesis [19] and demonstrating an association with the
hypoxic tumour microenvironment in nodal and liver metastases [20].
This study examined the distribution of tryptase(+) MCs and the
expression of PAR-2 in primary tumours compared with adjacent
uninvolved mucosa, in an attempt to understand their role in the pro-
gression of colonic cancer. Moreover, we examined protein expres-
sion of NHERF1 and its relationship with PAR-2, with the aim to
investigate their supposed usefulness as tumour markers in CRC.
Materials and methods
Ethics statement
The study was approved by the Institutional Review Board of the
National Cancer Research Centre ‘Giovanni Paolo II’, Bari, Italy. Before
undergoing routine surgery, all patients were informed of the investiga-
tional nature of the study and provided their written informed consent,
authorizing the Institute to utilize their removed biological tissue accord-
ing to ethical standards.
Tissue specimens
A series of 115 colonic cases of pathologically confirmed primary
adenocarcinoma Not Otherwise Specified (NOS) matched with adjacent
cancer-uninvolved colonic mucosa was identified by a retrospective
search of the surgical pathology files of the Pathology Department of
our Institute.
Sections of 4-lm thickness were cut from formalin-fixed and
paraffin-embedded histological blocks and for each sample, the cancer
(C) and the paired NM present on the same slide were used for
comparison. Histopathologic features of the colon carcinoma tissue
specimens were confirmed by blinded review of the original pathology
slides, stained with routine haematoxylin and eosin.
Disease was staged according to the tumour-node-metastasis (TNM)
classification system of the American Joint Committee on Cancer [21].
The World Health Organization classification was used for pathologic
grading [22]. Assessment of LVI was based on examination of sections
stained with haematoxylin and eosin and was considered evident if at
least one cohesive clump of tumour cells was clearly visible within peri-
tumoural endothelial-lined spaces, both lymphatic channels and small
blood vessels—closely associated with primary invasive carcinoma [23].
Information regarding patient characteristics, including age, gender,
histological type, tumour site, depth of invasion, nodal status, distant
metastases, differentiation grade, LVI, TNM stage and EGFR status, was
collected from the Pathology Department of our Institute. The EGFR sta-
tus was realized in accordance with the EGFR pharmDxTM scoring guide-
lines. Results were reported as positive when a complete or incomplete
circumferential membrane staining was observed in at least 1% of the
tumour cells. Staining was defined as immunostaining of cell membranes
above background level and scored as follows: 1+=weak, 2+=moderate
and 3+=strong. The absence of membrane staining or cytoplasmic stain-
ing was reported as negative. The percentage of stained cells was
assessed as follows: 1–10, 10–50 and >50%. Slides were scored in a
blind manner by two independent observers, who were blinded to the
patients’ characteristics. In the case of disagreement, the EGFR status
was determined by consensus after simultaneous dual re-examination.
Immunohistochemistry and immunohistochemical
double staining
Sections were immunohistochemically stained for NHERF1 using stan-
dard immunoperoxidase techniques, as previously described [24].
Briefly, sections were deparaffinized with xylene, rehydrated through a
graded ethanol series and pre-treated with 0.01 M sodium citrate buffer
at pH 6.0 in water bath. After endogenous peroxidase activity blocking
with 0.3% H2O2 buffer solution, sections were incubated with a rabbit
polyclonal EBP50 antibody for NHERF1 (clone PA1-090; Affinity Biore-
agents, Golden, CO, USA; 1:150 dilution in PBS/BSA 1%) overnight at
4°C. Bound antibody was visualized with 3-amino-9-ethylcarbazole sub-
strate-chromogen (DakoCytomation, Glostrup, Denmark) in the dark and
counterstained with Mayer’s haematoxylin. As a positive internal control,
we used paraffin-embedded cells pellets from MCF-7 cell lines, express-
ing high levels of NHERF1. For negative controls, the primary antibody
was omitted and replaced by PBS pH 7.6.
Every serial section adjacent to that stained for NHERF1 was submit-
ted to immunohistochemical double staining, a procedure that combined
the two markers with the aim to analyse both density of MCs and the
expression of PAR-2. Following the epitope antigen retrieval with
0.01 M sodium citrate buffer at pH 6.0 in water bath, protein blocking
was performed with Tris-buffered saline pH 7.6/Bovine Serum Albumin
(BSA) 1% and then the slides were exposed overnight to a mixture of
antibodies directed against human MC-tryptase (clone FL-275, rabbit
polyclonal; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and
PAR-2 (clone SAM11, mouse monoclonal; Santa Cruz Biotechnology
Inc.; for both 1:150 dilution in Tris-buffered saline/BSA 1%). After
tissue rinsing in Tris-buffered saline 19 wash buffer, sections were
incubated with MACH 2 Double Stain (Polymer Detection Kit 2, mouse-
Horseradish Peroxidase + rabbit-Alkaline Phosphatase; Biocare Medical
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LLC, Concord, CA, USA) and bound antibodies were visualized with
3,3′-diamino-benzidine (DAB Chromogen Kit; Biocare Medical LLC) and
Vulcan Fast Red chromogens (Vulcan Fast Red Chromogen Kit 2; Bio-
care Medical LLC). Finally, the slides were counterstained with Mayer’s
haematoxylin and mounted with an aqueous mounting medium (Dako-
Cytomation). As a result, the staining with human MC-tryptase was
visualized as a bright fuchsin-red colour, whereas the immunostaining
of PAR-2 appeared as brown. In each assay, a section of CRC noted on
routine histological examination with extensive infiltration by MCs and
with the presence of muscularis mucosae served as positive control for
MC-tryptase and PAR-2 respectively. As a negative control, the primary
antibody was replaced with Tris-buffered saline/BSA 1%.
Immunohistochemical analysis for MCs was based on the appear-
ance of tryptase(+) MCs in the tissue stroma, as previously reported
[25]. To evaluate MC density, the stained sections were screened under
950 microscopic fields to identify representative fields. Then, MCs were
counted in six to eight non-overlapping 9200 microscopic fields, cover-
ing both peripheral and central regions (core) of each section. Cells
showing an equivocal staining or lacking a nucleus were not counted.
MC density in every histological section was expressed as a median
and interval of variation, which was used as cut-off to classify cases in
low (≤median) and high (>median) MC density.
Immunohistochemical analysis for PAR-2 and NHERF1 was based on
subcellular localization of analysed markers. For PAR-2 immunoreactiv-
ity, membranous/cytoplasmic localization was considered, whereas for
NHERF1, the cytoplasmic localization was examined. As previously
described [20], protein expression analysis was determined by multiply-
ing the number of stained cells (0–100) by the intensity staining (0, no
immunoreactivity; 1, weak; 2, moderate; 3, strong) in three to five repre-
sentative areas for each section at 9200 magnification. The total score
obtained (0–300) was therefore converted to a percentage of stained
positive cells/section. Moreover, the median value of positive cells was
used as a cut-off to group cases into two categories of negative (≤med-
ian) and positive (>median) expression. All stained samples were scored
in a blind manner by two independent investigators who had no prior
knowledge of the clinicopathological data. When a section was uninfor-
mative—either lost or contained no tumour tissue—a case was judged
as ‘not evaluable’ in the statistical analysis. Photomicrographs were
acquired under bright-field illumination with a Leica DMLB optical micro-
scope (Leica, Cambridge, UK), coupled with a Leica DCC camera (Leica).
Immunohistofluorescence
Immunofluorescent analysis was performed as previously described
[20]. Briefly, after antigen retrieval, tissues were incubated overnight at
4°C in a humidified chamber with the rabbit policlonal antibody anti-
NHERF1 (clone PA1-090, 1:150 dilution; Affinity Bioreagents) and with
the mouse monoclonal anti-PAR-2 (clone SAM11, 1:150 dilution; Santa
Cruz Biotechnology Inc.). Slides were then incubated at room tempera-
ture for 1 hr with the Alexa Fluor 488 and Alexa Fluor 568 immunoglob-
ulin G secondary conjugated antibodies (1:2000 dilution; Molecular
Probes Inc., Eugene, OR, USA).
Images were obtained on a BX40 microscope (Olympus, Tokyo,
Japan) with a SenSys 1401E-Photometrics charge–coupled device cam-
era. To verify protein co-localization, each acquired stack was merged
by transforming the two channels corresponding to red (tetramethyl-
rhodamine B isothiocyanate) and green (fluorescein isothiocyanate) into
a single two-colour stack using the ‘RGB merge’ command of ImageJ
software (National Institutes of Health Bethesda, MD, USA).
Statistical analysis
The non-parametric Mann–Whitney U-test was used to compare expres-
sion levels of tumour markers considered within C and NM compart-
ments. Association analysis between tumour markers and
clinicopathological data was analysed using a v2 or Fisher’s exact tests.
Correlation between two continuous variables was assessed by the non-
parametric Spearman’s rank test. All tests were two sided with a 95%
CI and a P < 0.05 was considered statistically significant. Data analysis
was carried out using the statistical package SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Patients
This study considered 115 patients, consisting of 66 men (57.4%)
and 49 women (42.6%), with a median age of 66 years (range 40–
89 years). Location of cancer was colon and rectum in 73 (64%) and
41 (36%) patients respectively. Sixty-two (62.6%) patients presented
lymph node metastases at the time of diagnosis and 47 (45.6%) had
synchronous distant metastases. Seven tumours (6%) were classified
as well-differentiated, 57 (50%) as moderate and 50 (43.9%) as
poorly differentiated. Based on the TNM stage classification, there
were 18 (15.7%) stage I patients, 19 (16.5%) stage II patients, 27
(23.5%) stage III patients and 51 (44.3%) stage IV patients.
The clinicopathological characteristics of the 115 tumours analy-
sed are summarized in Table 1.
Protein expression analysis of tryptase(+) MCs
and PAR-2
We carried out an immunohistochemical double-staining assay to
examine the distribution of mucosal MCs and to determine PAR-2
levels, obtaining bright fuchsine-red and brown-coloured precipi-
tates at the antigen sites of cancer and corresponding normal
mucosa compartments of the same colonic tumour respectively
(Fig. 1A). Infiltration of MCs was already present in the uninvolved
compartment of each sample, distributed in the lamina propria and
submucosa (Fig. 1A, upper panel). Conversely, PAR-2 was lowly
expressed or not detectable in epithelial cells of normal mucosa
(Fig. 1A, upper panel).
In the tumour compartment, we observed MCs located mainly in
the connective stroma, in the interface between growing cancer and
healthy tissue and, frequently, in close association with small blood
vessels within the tumour microenvironment. Interestingly, MCs were
also present within the core of the invasive tumours and foci of micr-
oinvasion of the tumour mass (Fig. 1A, lower panel). In contrast,
immunoreactivity for PAR-2 was detected both at the tumour centre
and at the invasive front of the lesion. However, a higher intensity of
staining could be detected along the invasion front and in most cases,
along tumour borders adjacent to vascular structures (Fig. 1A, lower
ª 2013 The Authors.
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panel). In particular, PAR-2 was strongly expressed on cytoplasm or
focally localized on membranous surface of epithelial tumour cells.
The distribution of MCs and PAR-2 immunoreactive epithelial cells
in colonic tumours is summarized in Figure 1B and C respectively.
The MC count significantly decreased passing from adjacent NM
towards C tissue [median 79.15 (range 22.5–192.7) versus 56.3
(15.8–97.8), respectively; P < 0.0001, by Mann–Whitney test]. More-
over, a statistically higher median expression of PAR-2 was observed
in C compared with NM [2.7 (0–17.7) versus 26.5 (6.7–62.0), respec-
tively; P < 0.0001].
PAR-2 expression was evaluated both on the entire section and at
the sites where MCs most intensively accumulated in serial sections
(Fig. 2). Intriguingly, we noted a more distinct immunoreactivity
(Fig. 2A) and a statistically higher median value of PAR-2 at the sites
most infiltrated by MCs than in areas with low density of MCs [34.4
(7.7–78.4) versus 26.5 (6.7-62.0), respectively; P < 0.0001; Fig. 2B).
Protein expression analysis of NHERF1
In normal mucosa, NHERF1 expression was detected at the apical
pole of the well-polarized duct, with a characteristic distribution
along apical cell membranes of both enterocytes and goblet cells
(Fig. 3A, upper panel). In the cells of all tumour samples, a variable
cytoplasmic NHERF1 expression was detected. Positive cells had no
Table 1 Clinicopathological data and tumour marker expressions in
115 colorectal cancers
Characteristics, n (%) Total (n = 115)
Age at diagnosis, median (range) 66 (40–89)
Gender
Male 66 (57.4)
Female 49 (42.6)
Histological type
Adenocarcinoma (NOS) 115 (100.0)
Tumour site
Colon 73 (63.5)
Rectum 42 (36.5)
Depth of invasion
pT1 4 (3.5)
pT2 18 (15.7)
pT3 69 (60.0)
pT4 24 (20.9)
Nodal status
pN0 43 (37.4)
pN1 32 (27.8)
pN2 37 (32.2)
pN3 3 (2.6)
Distant metastases
M0 68 (59.1)
M1 47 (40.9)
Differentiation grade
Well 7 (6.1)
Moderate 57 (50.0)
Poor 50 (43.9)
LVI
Absent 60 (68.2)
Present 28 (31.8)
TNM stage
I 18 (15.7)
II 19 (16.5)
Table 1. Continued
Characteristics, n (%) Total (n = 115)
III 27 (23.5)
IV 51 (44.3)
EGFR
Negative 49 (73.1)
Positive 18 (26.9)
MC density
Low (≤56) 59 (51.3)
High (>56) 56 (48.7)
PAR-2 expression
Negative (≤26) 61 (53.0)
Positive (>26) 54 (47.0)
Cytoplasmic NHERF1 expression
Negative (≤44%) 58 (50.4)
Positive (>44%) 57 (49.6)
Adenocarcinoma (NOS): adenocarcinoma Not Otherwise Specified;
LVI: lymphovascular invasion; EGFR: epidermal growth factor recep-
tor; MC density: density of tryptase(+) Mast Cell; PAR-2: Proteinase-
Activated Receptor 2; NHERF1: Na+/H+ exchanger regulating factor 1.
1028 ª 2013 The Authors.
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C
Fig. 1 Expression analysis of tryptase-positive mast cells and PAR-2 in human colorectal cancer. (A) Representative images of tryptase(+) MCs
(arrowheads) and PAR-2 immunoreactivity in primary tumours matched with adjacent cancer-uninvolved colonic mucosa by immunohistochemical
double staining (original magnification on the left 9100, enlargement on the right 9200). (B and C) The MC density and the distribution of PAR-2
(+) cells, respectively, on normal mucosa and the tumour compartment of the same colonic lesion. (Horizontal bold line in each box = median
value; ***P < 0.0001).
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preferential distribution. In fact, they could be observed either along
the invasion front or within the growing tumour mass (Fig. 3A, lower
panel).
A higher density of epithelial cells positive for cytoplasmic
NHERF1 was observed in C compared with NM [44.5 (5.7–80.0) ver-
sus 2.5 (0–60.0) respectively] and the intergroup comparison showed
that the median expression of NHERF1 was statistically higher in the
C compartment than in NM (P < 0.0001; Fig. 3B).
Association of clinicopathological data with MC
density, PAR-2 and NHERF1 expressions
Significant associations between tumour markers and clinicopatho-
logical characteristics are summarized in Table 2. In particular, a high
density of tryptase(+) MCs was shown in 48.7% (n = 56/115) of
tumours, exhibiting a statistical association with male patients
(P = 0.004) and higher TNM stage (P = 0.025); a statistical trend
was observed between the high density of tryptase(+) MCs and
tumours with a poor differentiation grade (P = 0.051).
Positive expression of PAR-2 was observed in 47% (n = 54/115)
of tumours and these overexpressed cases showed a significant
association with high nodal status, the presence of distant metastases
(P = 0.007 and P = 0.002, respectively, data not shown), higher
TNM stage (P = 0.000), poor differentiation grade (P = 0.005) and
the presence of LVI (P = 0.010).
Tumours overexpressing cytoplasmic NHERF1 (49.6%) showed a
significant association with pT3-pT4 depth of invasion, high nodal
status, the presence of distant metastases (P = 0.000 for all, data not
shown), higher TNM stage (P = 0.000), poor differentiation grade
(P = 0.000) and the presence of LVI (P = 0.000). Finally, tumours
overexpressing cytoplasmic NHERF1 showed a significant trend with
positive EGFR status (P = 0.053).
Correlation among MC density, PAR-2 and
NHERF1 expressions
A direct association existed between high MC density and PAR-2
overexpression. In fact, the Spearman’s rank test revealed a positive
A
B
Fig. 2 Comparison of PAR-2 expression in
low and high mast cell density tumour
areas. (A) Two representative images of
PAR-2 immunoreactivity in colonic tumour
areas with low and high MC counts by
immunohistochemical double staining (ori-
ginal magnification on the left 9100,
enlargement on the right 9200). (B) The
distribution of PAR-2(+) cells, evaluated
on the whole section with low MC density
and at the sites where MCs most inten-
sively accumulated in tumour lesion. (Hor-
izontal bold line in each box = median
value; ***P < 0.0001).
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correlation between tryptase(+) MCs and PAR-2 both in NM
(r = 0.299, P = 0.002; Table 3B) and C compartments (r = 0.193,
P = 0.039; Table 3A). A direct association existed between PAR-2
overexpression and increasing levels of NHERF1. The Spearman’s
rank test showed a significant positive correlation between PAR-2
and cytoplasmic NHERF1 both in NM (r = 0.319, P = 0.001;
Table 3B) and C compartments (r = 0.362, P < 0.000; Fig. 4A). This
association was also observed in immunofluorescence analysis,
showing a co-overexpression of the two proteins in C samples.
Tumour cells disseminated in the stroma and, frequently, very close
to blood vessels within the tumour microenvironment, overexpressed
PAR-2 and NHERF1, showing a wide co-localization of the two pro-
teins in the cytoplasm compartment (Fig. 4B).
Given the fundamental association between these two tumour
markers, we examined the potential prognostic role of the PAR-2/
NHERF1 immunophenotypes. With respect to the PAR-2()/cytoplas-
mic NHERF1() expression phenotype, the PAR-2(+)/cytoplasmic
NHERF1(+) phenotype was associated with the highest depth of inva-
sion (P = 0.004), positive nodal status (P < 0.000), the presence of
distant metastases (P < 0.000), poor differentiation grade
(P < 0.000) and the presence of LVI (P = 0.000; Table 4).
Furthermore, a significant correlation was highlighted between
high MC density and increasing levels of cytoplasmic NHERF1 in the
NM compartment (r = 0.349, P = 0.000; Table 3B).
Discussion
Although a variety of malignant tumours are accompanied by an
increased infiltration of MCs, conflicting data about the relationship
between MC density and prognosis in CRC have been reported. In
fact, although some authors have found a direct correlation between
high MC counts and improved prognosis [26, 27], the majority of
studies have shown that MCs are directly associated with an unfa-
vourable prognosis and tumour aggressiveness [28–31]. In this
study, we investigated the distribution of MCs and their relationship
with PAR-2(+) epithelial cells in primary CRC. Using the immunohis-
tochemical double staining technique, we analysed the density of
A
B
Fig. 3 Expression analysis of cytoplasmic
NHERF1 in human colorectal cancer. (A)
Representative images of cytoplasmic
NHERF1 immunoreactivity in the primary
tumour matched with adjacent cancer-
uninvolved colonic mucosa by immuno-
histochemistry (Original magnification on
the left 9100, enlargement on the right
9200). (B) The distribution of cytoplasmic
NHERF1(+) cells on normal mucosa and
the tumour compartment of the same
colonic lesion. (Horizontal bold
line = median value; ***P < 0.0001).
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tryptase(+) MCs and the expression of PAR-2 in tumours and adja-
cent uninvolved colonic mucosa.
In this study, we showed a large distribution of MCs in the
lamina propria and submucosa, representing an early and persis-
tent infiltrating immune cell type. In line with findings from Xia
et al. [32], we confirmed that the MC count in normal mucosa
was higher than that in primary tumours. Interestingly, we also
demonstrated a significant MC increase in male patients compared
with female patients in agreement with Wu et al. [33]. This strong
association seems to be related to the oestrogen/oestrogen recep-
tor/tumour necrosis factor-a axis; in fact, MCs express oestrogen
receptors and treatment with the specific ligand has been demon-
strated to prevent the release of TNF-alpha, a major MC-derived
autocrine growth factor [34].
In our study, MCs infiltrated stroma more abundantly at inva-
sive margins than in the internal tumour field, probably to activate
cell processes involved in cancer progression. Furthermore, we
showed that tumours with distant metastases and with a poor dif-
ferentiation grade had a higher density of tryptase(+) MCs. Tryp-
tase(+) MCs have been demonstrated to play a role in tissue
remodelling during wound healing and cancer, degrading selectively
matrix proteins, synthesizing collagen [35] and stimulating
Table 2 Association between tumour marker expressions and clinicopathological data in 115 colorectal cancers
Characteristics, n (%)
MC density PAR-2 expression
Cytoplasmic NHERF1
expression
Low High Negative Positive Negative Positive
Gender
Male 26 (39.4) 40 (60.6) 31 (47.0) 35 (53.0) 32 (48.5) 34 (51.5)
Female 33 (67.3) 16 (32.7) 30 (61.2) 19 (38.8) 26 (53.1) 23 (46.9)
P value 0.004 NS NS
TNM stage
I + II 17 (45.9) 20 (54.1) 23 (62.2) 14 (37.8) 28 (75.7) 9 (24.3)
III 20 (74.1) 7 (25.9) 21 (77.8) 6 (22.2) 23 (85.2) 4 (14.8)
IV 22 (43.1) 29 (56.9) 17 (33.3) 34 (66.7) 7 (13.7) 44 (86.3)
P value 0.025 0.000 0.000
Differentiation grade
High 6 (85.7) 1 (14.3) 5 (71.4) 2 (28.6) 5 (71.4) 2 (28.6)
Moderate 31 (54.4) 26 (45.6) 37 (64.9) 20 (35.1) 39 (68.4) 18 (31.6)
Poor 22 (44.0) 28 (56.0) 19 (38.0) 31 (62.0) 14 (28.0) 36 (72.0)
P value 0.051 0.005 0.000
LVI
Negative 34 (56.7) 26 (43.3) 42 (70.0) 18 (30.0) 44 (73.3) 16 (26.7)
Positive 10 (35.7) 18 (64.3) 11 (39.3) 17 (60.7) 8 (28.6) 20 (71.4)
P value NS 0.010 0.000
EGFR
Negative 23 (46.9) 26 (53.1) 25 (51.0) 24 (49.0) 28 (57.1) 21 (42.9)
Positive 12 (66.7) 6 (33.3) 10 (55.6) 8 (44.4) 5 (27.8) 13 (72.2)
P value NS NS 0.053
MC density: density of Tryptase-positive Mast Cell; PAR-2: Proteinase-Activated Receptor 2; NHERF1: Na+/H+ exchanger regulating factor 1; NS:
not significant; LVI: lymphovascular invasion.
Significant associations (P < 0.05) are indicated in bold.
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fibroblast proliferation [36] and myofibroblast differentiation [25].
However, it has been suggested that in the context of developing
tumours, the ability of MCs to remodel tissues is subverted, dis-
rupting the surrounding extracellular matrix and increasing tumour
spread [37]. In normal colonic mucosa, natural inhibitors of tryp-
tase and normal tissue homeostasis maintain a proteolytic balance,
even if during cancer progression, this balance is gradually dis-
turbed and definitively broken in the invasive CRC by overexpres-
sion of several proteases [38]. On the basis of our results, it
seems that MCs might functionally contribute to neoplastic aggres-
siveness by secreting tryptase, which increases tumour invasion
and metastasis [39, 40].
Recent studies have altered the traditional view of the role of
proteases in tumour evolution, showing that these enzymes serve
as signal molecules controlling cell functions through specific mem-
brane receptors [41]. In this context, it has been suggested that
PAR-2 may play an active role in the setting of cancer growth and
tumour progression (Fig. 5) [42–47]. Furthermore, most colon can-
cer cell lines express PAR-2 and its activation has shown to play
an important role in the progression of colon cancer [10]. In our
study, we demonstrated an increased expression of PAR-2 in can-
cer with respect to adjacent normal mucosa and PAR-2 overexpres-
sion was associated with advanced disease parameters, as
measured by TNM stage, poor histological differentiation and LVI.
Furthermore, we described a positive linear correlation between MC
density and PAR-2 expression, hypothesizing that tryptase may act
directly on PAR-2 by stimulating cancer progression. In fact, analo-
gous results have been reported for trypsin, a serine proteinase
similar to tryptase, which regulates cellular proliferation in gastric
carcinoma [48] and promotes colon cancer proliferation by inducing
PAR-2/G protein signalling pathways (Fig. 5) [10]. Thus, our data
could support the view that PAR-2 expression is related to the pro-
gression of CRC and its tryptase-induced activation could have a
role in tumour invasion.
Mounting evidence highlights the role of cytoplasmic adapter pro-
teins that contribute critically to the signalling, trafficking and function
of many G protein–coupled receptors [49]. In our previous studies, it
was established that NHERF1, an adaptor protein with two non-
identical, type 1 tandem PDZ domains and a carboxyl-terminal ezrin-
binding domain, is a potential candidate of clinical relevance for
human breast cancer [16, 24, 50, 51]. Recently, we have also demon-
strated that nuclear NHERF1, present in the early stages of colorectal
carcinogenesis and related with poor prognosis, might contribute to
the onset of the colonic malignant phenotype [19]. Furthermore, we
have suggested nuclear NHERF1 as a potential new biomarker of
advanced CRC, demonstrating an overexpression of nuclear NHERF1
in no longer polarized epithelial cells, converted to a mesenchymal
phenotype in hypoxic colonic areas [20]. Therefore, given that the role
of nuclear NHERF1 has been previously analysed in-depth and consid-
ering that reports investigating the distribution of cytoplasmic NHERF1
in CRC have not been published to date, in this study, we aimed to
analyse the role of the NHERF1 protein localized in the cytoplasm. We
demonstrated that overexpressing tumours resulted associated with
unfavourable prognosis and aggressive clinical parameters. Moreover,
we showed both a positive linear correlation between cytoplasmic
NHERF1 and PAR-2 and a significant co-expression of the two
proteins mostly in the margin of the tumour mass.
Even if PAR-2 expression was associated with clinicopathological
characteristics of adverse prognosis, in some studies, PAR-2 has
not represented an independent prognostic factor [52, 53]. Other
markers interacting with the PAR-2 signalling pathway may be the
reason of this trend, which influences survival outcome. Thus, study
of PAR-2 expression in CRC in combination with other proteins
could be helpful in evaluating the relationship of PAR-2 with patient
survival [52]. We therefore examined the potential prognostic role of
PAR-2/NHERF1 immunophenotypes on the basis of the significant
correlation between these two tumour markers. Interestingly, the
PAR-2(+)/cytoplasmic NHERF1(+) expression immunophenotype
was able to predict poor prognosis of CRC patients, being associ-
Table 3 Correlation analysis among Mast Cell density, PAR-2 and
NHERF1 expressions in primary cancer (A) and paired normal colo-
nic mucosa (B)
Variables MC density PAR-2 Cytoplasmic NHERF1
(A)
MC density
Rho 1 0.1931 0.167
P value – 0.039 0.074
PAR-2
Rho 0.1931 1 0.3621
P value 0.039 – <0.000
Cytoplasmic NHERF1
Rho 0.167 0.3621 1
P value 0.074 <0.000 –
(B)
MC density
Rho 1 0.2989 0.3485
P value – 0.002 0.000
PAR-2
Rho 0.2989 1 0.3191
P value 0.002 – 0.001
Cytoplasmic NHERF1
Rho 0.3485 0.3191 1
P value 0.000 0.001 –
MC density: density of Tryptase-positive Mast Cell; PAR-2: Protein-
ase-Activated Receptor 2; NHERF1: Na+/H+ exchanger regulating fac-
tor 1.
Significant correlations (P < 0.05) are indicated in bold.
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AB
Fig. 4 Analysis of PAR-2 and cytoplasmic NHERF1 in human colorectal cancer. As shown in (A), the correlation between protein expression of PAR-
2 and cytoplasmic NHERF1 was evaluated by Spearman’s rank correlation coefficient analysis, and a positive significant correlation was established.
(B) A representative tissue sample stained with PAR-2 and EBP-50 antibodies and detected with Alexa Fluor 568 (red) and Alexa Fluor 488 (green)
secondary antibodies, respectively, prior to fluorescence microscopy analysis. Overlaps between red and green signals (merged) point to co-localiza-
tions (in yellow). Arrowheads indicate invasive cells disseminated into the stroma close to a blood vessel with a high global expression of two pro-
teins, where PAR-2 co-localized with NHERF1 on cytoplasmic and membranous compartments (scale bar = 20 lm).
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ated with the presence of nodal and distant metastasis, poor differ-
entiation grade and LVI.
In conclusion, our findings show that the high density of tryptase
(+) MCs correlates with the advanced stages of CRC. Furthermore,
the strong association between tryptase(+) MCs and PAR-2 expres-
sion seems to suggest that the activation of tryptase-induced PAR-2
contributes to tumour progression and invasiveness. Furthermore,
examination of the PAR-2(+)/cytoplasmic NHERF1(+) expression
immunophenotype appears able to predict the prognosis of CRC and
may be useful for selecting subgroups of patients who should be trea-
ted with more aggressive therapies because of the higher risk of
tumour invasion and metastasis.
Finally, we believe that further studies are needed to confirm use-
fulness of PAR2(+)/cytoplasmic NHERF1(+) expression immunophe-
notype for selecting subgroups of patients who should be treated
with more aggressive therapies.
Acknowledgements
The authors thank Vincenza Rubini, Rossana Daprile and Alessia L. Marzano
for their expert technical assistance. The authors also thank Caroline Oakley
for language revision.
Conflict of interest
No authors have conflicts of interest to declare.
Table 4 Association between PAR-2/NHERF1 expression immun-
ophenotypes and clinicopathological data
Characteristics,
n (%)
PAR-2(+)/
cytoplasmic
NHERF1(+)
PAR-2()/
cytoplasmic
NHERF1()
P value
Depth of invasion
pT1 0 (0.0) 3 (100.0) 0.004
pT2 2 (14.3) 12 (85.7)
pT3 28 (57.1) 21 (42.9)
pT4 7 (58.3) 5 (41.7)
Nodal status
pN0 7 (21.9) 25 (78.1) <0.000
pN1 10 (41.7) 14 (58.3)
pN2 17 (89.5) 2 (10.5)
pN3 3 (100.0) 0 (0.0)
Distant metastases
M0 8 (20.0) 32 (80.0) <0.000
M1 26 (92.9) 2 (7.1)
Differentiation grade
Well 1 (20.0) 4 (80.0) <0.000
Moderate 13 (28.9) 32 (71.1)
Poor 22 (75.9) 7 (24.1)
LVI
Negative 10 (21.7) 36 (78.3) 0.000
Positive 13 (76.5) 4 (23.5)
PAR-2: Proteinase-Activated Receptor 2; NHERF1: Na+/H+ exchanger
regulating factor 1; LVI: lymphovascular invasion.
Significant associations with P < 0.05 are indicated in bold.
Fig. 5 Diagram showing the major G protein–mediated signalling
pathways coupled to PAR-2. Tryptase secreted in the tumour microen-
vironment by infiltrating mast cells cleaves the N-terminal domain of
PAR-2, releasing a new N-terminal tail, which acts as a tethered ligand
that binds the receptor itself. The association with G proteins initiates
signal transduction, resulting in stimulation of phosphoinositide break-
down, cytosolic calcium mobilization and promoting several cell
responses.
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